Effects of intravenous Lidocaine on MAC of Sevoflurane - MAC of Sevo with Lidocaine

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2010-018276-25-AT

Enrollment

150

Registered

2010-12-07

Start date

2010-12-16

Completion date

Unknown

Last updated

2015-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The effects of intravenous application of Lidocaine on the MAC during Sevofluran Narcosis should will be investigated

Interventions

Trade Name: Xylanaest purum 2%- Ampullen Pharmaceutical Form: Injection* INN or Proposed INN: LIDOCAINE CAS Number: 137-58-6 Concentration unit: mg/kg milligram(s)/kilogram Concentration type: up to C

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: operation under general Anesthesia insertion of LMA possible Age 30-65 ASA Class 1-2 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: known arrhythmias known epilepsia

Design outcomes

Primary

Measure	Time frame
Main Objective: To evaluate the effect of Lidocaine on MAC of Sevoflurane;Secondary Objective: To evaluate the effect of Lidocaine on BIS, haemodynamics and PI under Sevoflurannarcosis;Primary end point(s): movement or no movement as reaction to skin incision	—

Countries

Austria

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026